Highly read articles about RA feature treatment response, comorbidities

The most highly read research into patients with rheumatoid arthritis is focused on response to treatments, tracking disease progression and comorbidities.

Remaining pain after response to treatment of rheumatoid arthritis (RA) has also been of interest to readers of Healio Rheumatology.

Comorbidity at disease onset seen in half of patients with early RA

Comorbidities were common among patients with early RA, with a considerable number of added comorbidities observed through 5 years of follow-up, suggesting inflammation may play a key role in the context of disease and comorbidities, according to recently published research. Read more.

Pain remains for many patients with early RA after treatment with methotrexate

Patients with early RA treated with methotrexate had remaining pain, despite a good response to treatment, according to a study by researchers from the Karolinska Institute in Stockholm. Read more.

Ultrasound may identify early joint changes from abatacept in patients with RA

Power Doppler and grayscale ultrasound scores were responsive to changes in joints following administration of abatacept to patients with RA, according to published study data. Read more.

Opioid use may increase infection risk for patients with RA

Use of opioid analgesics by patients with RA may increase the risk for hospitalization due to serious infection, according to researchers from Vanderbilt University Medical Center. Read more.

Clinical trial approved in U nited K ingdom for biosimilar to rituximab for RA

JHL Biotech Inc. announced the United Kingdom’s Medicines and Healthcare Products Regulatory Agency has authorized the company to begin a clinical trial for JHL1101, a biosimilar to rituximab, for patients with RA, according to a company press release. Read more.